

# GLA:D to provide high value care for people with osteoarthritis







#### **A/Prof Christian Barton**

GLA:D Australia program co-lead

La Trobe Sport and Exercise Medicine Research Centre, Melbourne, Australia

Department of Physiotherapy, Podiatry and Prosthetics and Orthotics, School of Allied Health, Human Services and Sport, La Trobe University, Bundoora, Australia



Sport and Exercise Medicine Research Centre

### 1. Effective first-line care for osteoarthritis



2. Evidence/guideline practice gap

## 3. GLA:D as a solutions to support first-line care implementation





TODAY

Sport and Exercise Medicine Research Centre



		Control is better	Exercise is better	
Author	Publicationsyear			SMD (95% CI)
Kovar Weidenhielm Børjesson Schilke Bautch Ettinger -ae Ettinger -rt Røgind Maurer Péloquin Horstmann Petrella Baker Fransen-gr Gür Topp	1992 1993 1996 1997 1997 1997 1997 1998 1999 2000 2000 2000 2001 2001 2001 2001			<ul> <li>0.63 (0.21, 1.06)</li> <li>0.36 (-0.25, 0.98)</li> <li>0.34 (-0.03, 0.70)</li> <li>0.49 (0.01, 0.96)</li> <li>0.57 (0.15, 1.00)</li> <li>0.51 (0.21, 0.82)</li> <li>0.46 (0.22, 0.70)</li> <li>0.49 (0.25, 0.72)</li> <li>0.44 (0.23, 0.65)</li> <li>0.43 (0.25, 0.61)</li> <li>0.49 (0.32, 0.66)</li> <li>0.59 (0.38, 0.79)</li> <li>0.57 (0.38, 0.76)</li> </ul>
Talbot Talbot Huang-a Keefe-CST Keefe Cheing McCarthy Messier - ex Messier - ex+d Rosemffet Huang-b Thorstensson Rooks	2002 2003 2004 2004 2004 2004 2004 2004			$\begin{array}{c} 0.57 \\ (0.37, 0.73) \\ 0.55 \\ (0.37, 0.73) \\ 0.58 \\ (0.40, 0.76) \\ 0.55 \\ (0.37, 0.73) \\ 0.54 \\ (0.36, 0.72) \\ 0.52 \\ (0.34, 0.70) \\ 0.51 \\ (0.34, 0.67) \\ 0.47 \\ (0.30, 0.65) \\ 0.46 \\ (0.30, 0.65) \\ 0.45 \\ (0.29, 0.61) \\ 0.45 \\ (0.29, 0.60) \\ 0.43 \\ (0.28, 0.59) \\ 0.43 \\ (0.28, 0.59) \\ 0.43 \\ (0.28, 0.59) \\ 0.43 \\ (0.28, 0.58) \\ \end{array}$
An Lim Jan-h Jan-I Tsauo Lund-aq Lund-Ib Evgeniadis Aglamis Weng Lee Lin-PrT Lin-ST Jan Trans -Vibf	2008 2008 2008 2008 2008 2008 2008 2009 2009			0.44 (0.29, 0.59) 0.45 (0.30, 0.59) 0.46 (0.31, 0.60) 0.46 (0.32, 0.60) 0.46 (0.32, 0.60) 0.45 (0.31, 0.58) 0.44 (0.31, 0.57) 0.43 (0.30, 0.56) 0.43 (0.31, 0.56) 0.43 (0.31, 0.56) 0.43 (0.31, 0.56) 0.43 (0.32, 0.56) 0.43 (0.33, 0.57) 0.45 (0.33, 0.57)
Trans -Vibm Trans -Vibm McKnight Bezalel Ni Salli-Isom Wang-aq Wang-aq Wang-lb Lim-aq Lim-lb Foroughi Swank Sayers-high Sayers-slow Chang	2009 2010 2010 2010 2010 2010 2010 2011 2011 2011 2010 2010 2011 2011 2011 2012 2012 2012			$\begin{array}{c} 0.45 \ (0.33, 0.56) \\ 0.45 \ (0.33, 0.56) \\ 0.45 \ (0.33, 0.56) \\ 0.45 \ (0.34, 0.56) \\ 0.45 \ (0.34, 0.56) \\ 0.47 \ (0.35, 0.59) \\ 0.50 \ (0.34, 0.56) \\ 0.53 \ (0.40, 0.66) \\ 0.53 \ (0.40, 0.66) \\ 0.53 \ (0.40, 0.66) \\ 0.53 \ (0.40, 0.66) \\ 0.52 \ (0.39, 0.65) \\ 0.52 \ (0.39, 0.63) \\ 0.51 \ (0.39, 0.53) \\ 0.51 \ (0.39, 0$
Figure by Carsten Juhl 2014 0 .25 .5 .75 1				

"As of 2002 sufficient evidence had accumulated to show significant benefit of exercise over no exercise in patients with osteoarthritis, and further trials are unlikely to overturn this result."

#### Osteoarthritis and Cartilage



Incremental clinical effectiveness and cost effectiveness of providing supervised physiotherapy in addition to usual medical care in patients with osteoarthritis of the hip or knee: 2-year results of the MOA randomised controlled trial

J.H. Abbott † \*, R. Wilson †, D. Pinto ‡, C.M. Chapple §, A.A. Wright ||, For the MOA Trial team<sup>a</sup>

Osteoarthritis and Cartilage 28 (2020) 907-916

#### Osteoarthritis and Cartilage

OSTEOARTHRITI


Cost-effectiveness of 12 weeks of supervised treatment compared to written advice in patients with knee osteoarthritis: a secondary analysis of the 2-year outcome from a randomized trial

S.T. Skou †‡§||\*, E.M. Roos ‡, M. Laursen †||¶, L. Arendt-Nielsen ||, S. Rasmussen †||¶, O. Simonsen † || ¶, R. Ibsen #, A.T. Larsen ††, J. Kjellberg ††

#### **Exercise-therapy + education are cost**effective v usual care or written advice







## UNIVERSITY

Sport and Exercise Medicine Research Centre

## Behaviour of people with knee osteoarthritis

- 17% meet physical activity guidelines (Wallis 2013)
- 43% engage with appropriate first line care (Runciman 2012)


#### Beliefs of people with knee osteoarthritis (Bunzli 2021)

#### >> impairment discourse dominates <<

- Wear and tear disease
- Fear of pain and damage
- Exercise is dangerous
- Surgery is inevitable




### What is effective care for osteoarthritis – guidelines (OARSI, NICE, RACGP, etc.)





Sport and Exercise Medicine Research Centre





Osteoarthritis management care pathways are complex and inefficient: A qualitative study of physiotherapist perspectives from specialised osteoarthritis services

Alison J. Gibbs<sup>1,2,3</sup>  $\circ$  | Jason A. Wallis<sup>2,4,5</sup>  $\circ$  | Nicholas F. Taylor<sup>2,6</sup> | Joanne L. Kemp<sup>1,2</sup> | Christian J. Barton<sup>1,2,7</sup>

*"It is challenging because GPs are telling them, ....I'm referring you to the hospital for a knee replacement"* 

"(People with osteoarthritis) have [been told it's] bone-onbone disease, their joints are crumbling"

*"I find it's really hit and miss with the physio that you're getting"* 



#### **RESEARCH ARTICLE**

**Open Access** 

CrossMark

#### The projected burden of primary total knee and hip replacement for osteoarthritis in Australia to the year 2030

Ilana N. Ackerman<sup>1,2\*</sup>, Megan A. Bohensky<sup>2</sup>, Ella Zomer<sup>1</sup>, Mark Tacey<sup>1,3,4</sup>, Alexandra Gorelik<sup>2,5</sup>, Caroline A. Brand<sup>1</sup> and Richard de Steiger<sup>6,7</sup>

- TKR and THR for OA is estimated to rise by 276% and 208%, respectively, by 2030
- The total cost to the healthcare system would be \$AUD5.32 billion



Osteoarthritis and Cartilage Open



Implementing a national first-line management program for moderate-severe knee osteoarthritis in Australia: A budget impact analysis focusing on knee replacement avoidance


Ilana N. Ackerman<sup>a,\*</sup>, Søren T. Skou<sup>b,c</sup>, Ewa M. Roos<sup>d</sup>, Christian J. Barton<sup>e,f</sup>, Joanne L. Kemp<sup>e</sup>, Kay M. Crosslev<sup>e</sup>, Danny Liew<sup>a</sup>, Zanfina Ademi<sup>a</sup>



Total cost savings for the year 2019

### Let's conservatively call it >\$300M each year





TRE



Sport and Exercise Medicine Research Centre



#### 3) Data collection of patient outcomes

All program participants are registered into an online participant data registry, with an 'opt out' consent process for contributing to collection of participant-reported data



















Sport and Exercise Medicine Research Centre





Tasm

## ~2,500 clinicians



Sport and Exercise Medicine Research Centre



Program evaluation of GLA:D® Australia: Physiotherapist training outcomes and effectiveness of implementation for people with knee osteoarthritis

Christian J. Barton<sup>a,b,c,\*</sup>, Joanne L. Kemp<sup>a,b</sup>, Ewa M. Roos<sup>d</sup>, Soren T. Skou<sup>d,e</sup>, Karen Dundules<sup>a,b</sup>, Marcella F. Pazzinatto<sup>a,b,f</sup>, Matthew Francis<sup>a,b</sup>, Natasha A. Lannin<sup>g,b</sup>, Jason A. Wallis<sup>a,b</sup>, Ray M. Crossley<sup>a,b,d</sup>



### FOR AUSTRALIANS WITH KNEE OSTEOARTHRITIS





'Real world' improvements in pain and quality of life following GLA:D® are consistent or better than what is found in controlled clinical trials evaluating exercise therapy for osteoarthritis




3 IN 4 PEOPLE

3 IN 4 PEOPLE

Repo meaningf in pain or 12-mo

Report clinically meaningful **improvement** in pain or quality of life at 12-month follow up desiring surgery before GLA:D® have **not had surgery** and **no longer desire surgery** at 12-month follow up





*System:* public/private funding to support participation.

*Patient:* patient demand; patient beliefs and understanding. *Program:* program promotion and awareness; data and evidence.

*Health services:* Conflicting managerial and organisational priorities; inadequate time to support program administration;

Health services: Fit of program to current services; Equipment and

*Health services*: staff resourcing and capacity to meet demand.

support; further professional development opportunity.

Program: Developing materials for CALD groups; central program

Health professional: referrer (e.g. GP) buy in.

Patient: patient motivation and commitment.

Program: program ethics and legal requirements.

**Barriers/Enablers** 

rural/regional location.

physical space; scheduling.

**Barriers/Enablers** 

Barriers/Enablers

**Barriers/Enablers** 

Program: Access to staff training.

**Barriers** 

Barriers

Barriers

Enablers

Effectiveness

Implementation

Maintenance

Adoption



"Funding in public health setting"

"GLA:D would also be easier to implement in my region if Medicare would fund (low socio-economic area and low patient numbers due to rural nature)"

## Health system funding remains the key barrier (and potential enabler)

#### TAKE HOMES

- 1. GLA:D provides an effective and cost-effective firstline care program
- 2. Although GLA:D is available in all states and territories, publicly funded offerings of the program remain limited
- 3. Improved health system funding (MBS, PHN, private health) to provide the program in the community at low or no cost would improve equity of access





Sport and Exercise Medicine Research Centre









